# The Angel in the Marble: Antibiotic Duration in the Neonatal Intensive Care Unit

**Authors:** Joseph B. Cantey, Dalyn B. Guinn

PMC · DOI: 10.3390/antibiotics15020228 · Antibiotics · 2026-02-20

## TL;DR

This paper reviews how long antibiotics should be given to infants in the NICU and suggests ways to safely shorten treatment durations.

## Contribution

The paper proposes a goal-based approach to determine optimal antibiotic duration in neonatal care.

## Key findings

- Current evidence on antibiotic treatment duration for neonates is limited and inconsistent.
- Shorter treatment durations could be investigated safely with a structured clinical approach.
- More research is needed in specific clinical scenarios to guide antibiotic stewardship.

## Abstract

Antimicrobial stewardship in the neonatal intensive care unit is a critically important tool to optimize clinical outcomes. The ideal duration of antimicrobial treatment is a key area that contains many knowledge gaps. This narrative review has three aims. One, to highlight the existing evidence for empiric and definitive antibiotic treatment durations for infants; two, to focus on clinical situations where further studies are needed; and three, to propose a rational, goal-based approach to clinical studies that provide for infant safety as shorter treatment durations are investigated.

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** pneumococcal, meningococcal, or Haemophilus influenzae type B meningitis (MESH:D008583), colonization (MESH:D003108), Bloodstream infection (MESH:D018805), stage III (MESH:D062706), brain abscesses (MESH:D001922), candidiasis (MESH:D002177), gut perforation (MESH:D057112), osteomyelitis (MESH:D010019), NEC (MESH:D020345), neonatal meningitis (MESH:D007232), abdominal distention (MESH:D000007), toxicity (MESH:D064420), UTIs (MESH:D014552), bronchopulmonary dysplasia (MESH:D001997), ventriculitis (MESH:D058565), infection (MESH:D007239), eczema (MESH:D004485), death (MESH:D003643), malabsorption (MESH:D008286), metabolic diseases (MESH:D008659), respiratory distress (MESH:D012128), Neonatal pneumonia (MESH:D011014), neonatal sepsis (MESH:D000071074), obesity (MESH:D009765), autoimmune diseases (MESH:D001327), intestinal perforation (MESH:D007416), Meningitis (MESH:D008580), asthma (MESH:D001249), extra-uterine growth failure (MESH:D051437), diabetes (MESH:D003920), dysbiosis (MESH:D064806), subdural empyema (MESH:D013354), inflammation (MESH:D007249), injury to (MESH:D014947), skin and soft tissue infections (MESH:D018461), metabolic syndrome (MESH:D024821)
- **Chemicals:** ceftriaxone (MESH:D002443), methicillin (MESH:D008712)
- **Species:** Pseudomonas (RNA similarity group I, genus) [taxon 286], Homo sapiens (human, species) [taxon 9606], Streptococcus sp. 'group B' (species) [taxon 1319], Klebsiella pneumoniae (species) [taxon 573], Escherichia coli (E. coli, species) [taxon 562]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938482/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12938482/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938482/full.md

---
Source: https://tomesphere.com/paper/PMC12938482